Home > Neurology > IHC 2021 > Pharmacological Treatment > Rimegepant confers long-term improvements in MMDs

Rimegepant confers long-term improvements in MMDs

Presented By
Evan Popoff, Broadstreet Health Economics & Outcomes Research, Canada

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Conference
IHC 2021
Trial
Phase 2, BHV3000-201
Rimegepant is a small-molecule calcitonin gene-related peptide (CGRP)-receptor antagonist, approved for both the acute and preventive treatment of migraine [1]. Acute treatment with this drug conferred long-term improvements in median time to 30% and 50% reduction in monthly migraine days (MMDs). This was found in a post hoc analysis of an open-label safety study [2]. The proportion of patients achieving a 30% or 50% reduction in MMDs relative to baseline is considered clinically meaningful and is therefore recommended as a primary or key secondary trial endpoint per the most recent guidelines [3,4]. BHV3000-201 (NCT03266588) was a 52-week, open-label, phase 2/3, multicentre, long-term safety study investigating rimegepant for the acute treatment of migraine [2]. Among >1,000 participants with ≥6 MMDs at baseline who were included in the curren...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on